share_log

NeuroSense Therapeutics To Present Data From PrimeC's Phase 2b Trial In ALS At Annual American Academy of Neurology Meeting

Benzinga ·  Apr 4 13:12

Two presentations in the General Neurology and Late Breaker sessions will respectively cover new clinical and microRNA data from NeuroSense

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 396

Recommended

Write a comment